Entrada Therapeutics, Inc. (TRDA) shareholders
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.09−0.08 (-1.55%)
Close on Nov 13, 2026Market cap $198.19MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.6%
29M of 39M shares
Institutional holders
129
27 new, 16 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
5 buys · 44 sales
Net sold $14.81M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (13.20%), Baker Bros. Advisors (GP) LLC (13.20%) and 1 more | 4,865,819 | 13.20% | 13D (active) amendment | Jun 24, 2024 |
| Kush Parmar Joint filing with Andrew J. Schwab (10.60%), 5AM Ventures V, L.P. (7.80%) and 2 more | 4,123,849 | 10.80% | 13D (active) amendment | Nov 14, 2025 |
| Ansbert Gadicke Joint filing with Luke Evnin (9.90%), Todd Foley (9.90%) and 2 more | 3,885,115 | 9.90% | 13D (active) amendment | Sep 8, 2026 |
| Roche Holding Ltd Joint filing with Roche Finance Ltd (6.90%) | 2,569,115 | 6.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 1,974,452 | 5.30% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TRDA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 5,072,730 | 13.03% | $37.34M | – | 0.19% |
| 5AM Venture Management, LLC | 4,056,379 | 10.42% | $29.85M | – | 10.37% |
| BlackRock, Inc. | 2,583,333 | 6.63% | $19.01M | +224,540 | 0.00% |
| Merck & Co., Inc. | 1,739,768 | 4.47% | $12.80M | New | 2.43% |
| Vanguard Capital Management LLC | 1,269,634 | 3.26% | $9.34M | +13,621 | 0.00% |
| Mpm Bioimpact LLC | 1,253,053 | 3.22% | $9.22M | New | 0.56% |
| TCG Crossover Management, LLC | 1,060,230 | 2.72% | $7.80M | −1,227,270 | 0.19% |
| Wellington Management Group Llp | 954,419 | 2.45% | $7.02M | −80,363 | 0.00% |
| Millennium Management LLC | 763,959 | 1.96% | $5.62M | +244,603 | 0.00% |
| StepStone Group LP | 761,277 | 1.96% | $5.60M | – | 0.26% |
| Geode Capital Management, LLC | 717,430 | 1.84% | $5.28M | +50,083 | 0.00% |
| Aqr Capital Management LLC | 699,537 | 1.80% | $5.15M | +620,044 | 0.00% |
| Nantahala Capital Management, LLC | 601,150 | 1.54% | $4.42M | +441,818 | 0.07% |
| State Street Corp | 596,677 | 1.53% | $4.39M | +62,879 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 542,316 | 1.39% | $3.99M | +16,273 | 0.00% |
| JPMorgan Chase & Co | 496,457 | 1.28% | $3.83M | +481,610 | 0.00% |
| Acadian Asset Management LLC | 400,862 | 1.03% | $2.95M | +67,693 | 0.00% |
| Citadel Advisors LLC | 394,323 | 1.01% | $2.90M | +179,305 | 0.00% |
| Dimensional Fund Advisors LP | 376,136 | 0.97% | $2.77M | +51,665 | 0.00% |
| Northern Trust Corp | 309,942 | 0.80% | $2.28M | +74,950 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 129 | 29M | 75.6% | 27 / 55 | 31 / 16 | 7M | 3M |
| Q1 2026 | 119 | 25M | 65.4% | 20 / 46 | 33 / 13 | 4M | 1M |
| Q4 2025 | 113 | 24M | 62.8% | 16 / 35 | 42 / 15 | 3M | 2M |
| Q3 2025 | 116 | 29M | 73.5% | 26 / 49 | 28 / 16 | 4M | 5M |
| Q2 2025 | 106 | 30M | 76.0% | 22 / 45 | 23 / 26 | 1M | 2M |
| Q1 2025 | 110 | 30M | 77.7% | 20 / 27 | 43 / 11 | 1M | 1M |
| Q4 2024 | 102 | 31M | 78.8% | 19 / 43 | 24 / 14 | 2M | 1M |
| Q3 2024 | 97 | 30M | 77.3% | 22 / 41 | 19 / 8 | 3M | 1M |
| Q2 2024 | 84 | 30M | 76.3% | 18 / 42 | 11 / 9 | 5M | 1M |
| Q1 2024 | 77 | 26M | 67.4% | 18 / 19 | 23 / 3 | 1M | 1M |
| Q4 2023 | 62 | 26M | 67.7% | 10 / 23 | 13 / 3 | 1M | 0M |
| Q3 2023 | 55 | 26M | 66.9% | 4 / 19 | 14 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
139 funds held TRDA in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TRDA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 953,727 | 2.45% | $7.02M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 768,028 | 1.97% | $5.65M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 322,233 | 0.83% | $2.19M | 0.01% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 295,981 | 0.76% | $2.18M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 283,038 | 0.73% | $2.08M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 271,022 | 0.70% | $1.99M | 0.01% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 175,405 | 0.45% | $1.29M | 0.12% | Jun 30, 2026 |
| iShares Biotechnology ETF | 150,880 | 0.39% | $1.11M | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 145,785 | 0.37% | $1.03M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 127,190 | 0.33% | $899.23K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 113,479 | 0.29% | $802.30K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 108,498 | 0.28% | $736.70K | 0.00% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 98,852 | 0.25% | $727.55K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 71,947 | 0.18% | $488.52K | 0.01% | Jul 31, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 70,280 | 0.18% | $496.88K | 0.04% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dipal Doshi | CEO, Director | 517,290 | 1.33% | Sep 3, 2026 |
| Kory James Wentworth | Chief Financial Officer | 117,277 | 0.30% | Sep 3, 2026 |
| Natarajan Sethuraman | President, Research & Develop. | 214,238 | 0.55% | Sep 3, 2026 |
| Nathan J. Dowden | President & COO | 196,060 | 0.50% | Sep 3, 2026 |
| Kush Parmar | Director | 3,784,650 | 9.72% | Aug 10, 2026 |
| Maha Radhakrishnan | Director | – | – | Jun 12, 2026 |
| Peter S. Kim | Director | 117,412 | 0.30% | Jun 12, 2026 |
| Mary Thistle | Director | – | – | Jun 12, 2026 |
| Bernhardt G. Zeiher | Director | 5,000 | 0.01% | Jun 12, 2026 |
| Gina Chapman | Director | – | – | Jun 12, 2026 |
| BioVentures 2018 LLC MPM | 10% owner | 4,144,952 | 10.65% | Sep 9, 2026 |
| Mpm Bioventures 2018, L.P. | 10% owner | 4,325,784 | 11.11% | Sep 9, 2026 |
| BioVentures 2018 GP LLC MPM | 10% owner | 3,885,115 | 9.98% | Sep 9, 2026 |
| MPM BioVentures 2014 (B), L.P. | 10% owner | 4,231,434 | 10.87% | Sep 9, 2026 |
| Todd Foley | 10% owner | 4,318,348 | 11.09% | Sep 9, 2026 |
| BioVentures 2014 GP LLC MPM | 10% owner | 4,144,952 | 10.65% | Sep 9, 2026 |
| Asset Management Investors Bv2018 Llc Mpm | 10% owner | 4,381,062 | 11.25% | Sep 9, 2026 |
| Ansbert Gadicke | 10% owner | – | – | Sep 9, 2026 |
| Asset Management Investors BV2014 LLC MPM | 10% owner | 4,325,784 | 11.11% | Sep 9, 2026 |
| BioVentures 2014 LLC MPM | 10% owner | – | – | Sep 9, 2026 |
| Mpm Bioventures 2018 (B), L.P. | 10% owner | 3,885,115 | 9.98% | Sep 9, 2026 |
| Luke Evnin | 10% owner | – | – | Sep 9, 2026 |
| MPM BioVentures 2014, L.P. | 10% owner | – | – | Sep 9, 2026 |
| 5AM Opportunities I (GP), LLC | 10% owner | – | – | Aug 10, 2026 |
| 5AM Ventures V, L.P. | 10% owner | 4,056,379 | 10.42% | Aug 10, 2026 |
| 5AM Partners V, LLC | 10% owner | – | – | Aug 10, 2026 |
| 5AM Opportunities I, L.P. | 10% owner | 4,256,379 | 10.93% | Aug 10, 2026 |
| Scott M. Rocklage | 10% owner | 3,877,094 | 9.96% | Aug 10, 2026 |
| Andrew J. Schwab | 10% owner | 4,283,379 | 11.00% | Aug 10, 2026 |
| Felix Baker | 10% owner | 380,152 | 0.98% | Nov 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| BioVentures 2018 GP LLC MPM 10% owner | Sep 9, 2026 | Sale | −28,837 | $7.13 | $205.61K | 3,885,115 |
| Mpm Bioventures 2018 (B), L.P. 10% owner | Sep 9, 2026 | Sale | −28,837 | $7.13 | $205.61K | 3,885,115 |
| BioVentures 2018 GP LLC MPM 10% owner | Sep 8, 2026 | Sale | −192,500 | $7.41 | $1.43M | 3,913,952 |
| Mpm Bioventures 2018 (B), L.P. 10% owner | Sep 8, 2026 | Sale | −192,500 | $7.41 | $1.43M | 3,913,952 |
| BioVentures 2018 GP LLC MPM 10% owner | Sep 4, 2026 | Sale | −38,500 | $7.11 | $273.74K | 4,106,452 |
| Mpm Bioventures 2018 (B), L.P. 10% owner | Sep 4, 2026 | Sale | −38,500 | $7.11 | $273.74K | 4,106,452 |
| BioVentures 2018 LLC MPM 10% owner | Sep 3, 2026 | Sale | −32,263 | $7.17 | $231.33K | 4,144,952 |
| BioVentures 2014 GP LLC MPM 10% owner | Sep 3, 2026 | Sale | −32,263 | $7.17 | $231.33K | 4,144,952 |
| Kory James Wentworth Chief Financial Officer | Sep 2, 2026 | Tax withholding | −1,733 | $7.14 | $12.37K | 117,277 |
| Nathan J. Dowden President & COO | Sep 2, 2026 | Tax withholding | −2,528 | $7.14 | $18.05K | 196,060 |
| BioVentures 2018 LLC MPM 10% owner | Sep 2, 2026 | Sale | −25,131 | $7.19 | $180.69K | 4,177,215 |
| Dipal Doshi CEO, Director | Sep 2, 2026 | Tax withholding | −8,724 | $7.14 | $62.29K | 517,290 |
| Natarajan Sethuraman President, Research & Develop. | Sep 2, 2026 | Tax withholding | −2,079 | $7.14 | $14.84K | 214,238 |
| BioVentures 2014 GP LLC MPM 10% owner | Sep 2, 2026 | Sale | −25,131 | $7.19 | $180.69K | 4,177,215 |
| BioVentures 2018 LLC MPM 10% owner | Sep 1, 2026 | Sale | −29,088 | $7.06 | $205.36K | 4,202,346 |
| BioVentures 2014 GP LLC MPM 10% owner | Sep 1, 2026 | Sale | −29,088 | $7.06 | $205.36K | 4,202,346 |
| BioVentures 2018 LLC MPM 10% owner | Aug 31, 2026 | Sale | −44,259 | $6.99 | $309.37K | 4,231,434 |
| MPM BioVentures 2014 (B), L.P. 10% owner | Aug 31, 2026 | Sale | −44,259 | $6.99 | $309.37K | 4,231,434 |
| BioVentures 2018 LLC MPM 10% owner | Aug 28, 2026 | Sale | −3,733 | $7.01 | $26.17K | 4,275,693 |
| MPM BioVentures 2014 (B), L.P. 10% owner | Aug 28, 2026 | Sale | −3,733 | $7.01 | $26.17K | 4,275,693 |
| BioVentures 2018 LLC MPM 10% owner | Aug 27, 2026 | Sale | −38,922 | $7.20 | $280.24K | 4,279,426 |
| MPM BioVentures 2014 (B), L.P. 10% owner | Aug 27, 2026 | Sale | −38,922 | $7.20 | $280.24K | 4,279,426 |
| BioVentures 2018 LLC MPM 10% owner | Aug 26, 2026 | Sale | −14,569 | $7.06 | $102.86K | 4,318,348 |
| Todd Foley 10% owner | Aug 26, 2026 | Sale | −14,569 | $7.06 | $102.86K | 4,318,348 |
| BioVentures 2018 LLC MPM 10% owner | Aug 25, 2026 | Sale | −26,522 | $7.54 | $199.98K | 4,332,917 |
| Todd Foley 10% owner | Aug 25, 2026 | Sale | −26,522 | $7.54 | $199.98K | 4,332,917 |
| BioVentures 2018 LLC MPM 10% owner | Aug 24, 2026 | Sale | −21,623 | $7.34 | $158.71K | 4,359,439 |
| Todd Foley 10% owner | Aug 24, 2026 | Sale | −21,623 | $7.34 | $158.71K | 4,359,439 |
| Kush Parmar Director | Aug 10, 2026 | Sale | −92,444 | $7.00 | $647.11K | 2,691,337 |
| Scott M. Rocklage 10% owner | Aug 7, 2026 | Sale | −52,317 | $6.85 | $358.37K | 2,783,781 |
| Kush Parmar Director | Aug 7, 2026 | Sale | −52,317 | $6.85 | $358.37K | 2,783,781 |
| Scott M. Rocklage 10% owner | Aug 6, 2026 | Sale | −10,494 | $7.00 | $73.46K | 2,836,098 |
| Kush Parmar Director | Aug 6, 2026 | Sale | −10,494 | $7.00 | $73.46K | 2,836,098 |
| Scott M. Rocklage 10% owner | Jul 31, 2026 | Sale | −1,718 | $6.85 | $11.77K | 2,846,592 |
| Kush Parmar Director, 10% owner | Jul 31, 2026 | Sale | −1,718 | $6.85 | $11.77K | 2,846,592 |
| Scott M. Rocklage 10% owner | Jul 30, 2026 | Sale | −114,756 | $6.93 | $795.26K | 2,848,310 |
| Kush Parmar Director, 10% owner | Jul 30, 2026 | Sale | −114,756 | $6.93 | $795.26K | 2,848,310 |
| Bernhardt G. Zeiher Director | May 20, 2026 | Buy | +5,000 | $5.86 | $29.30K | 5,000 |
| Natarajan Sethuraman President, Research & Develop. | May 4, 2026 | Sale(10b5-1 plan) | −25,907 | $15.39 | $398.71K | 216,317 |
| Nathan J. Dowden President & COO | May 4, 2026 | Sale(10b5-1 plan) | −15,000 | $15.33 | $229.95K | 198,588 |
| Nathan J. Dowden President & COO | May 4, 2026 | Option exercise | +15,000 | $1.74 | $26.10K | 213,588 |
| Kory James Wentworth Chief Financial Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −2,500 | $12.95 | $32.38K | 119,010 |
| Nathan J. Dowden President & COO | Mar 10, 2026 | Sale(10b5-1 plan) | −11,894 | $13.05 | $155.22K | 198,588 |
| Kory James Wentworth Chief Financial Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −11,388 | $13.02 | $148.27K | 121,510 |
| Nathan J. Dowden President & COO | Mar 9, 2026 | Sale(10b5-1 plan) | −3,116 | $13.02 | $40.57K | 210,482 |
| Kory James Wentworth Chief Financial Officer | Mar 9, 2026 | Sale(10b5-1 plan) | −5,089 | $13.00 | $66.16K | 132,898 |
| Kory James Wentworth Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −7,988 | $12.25 | $97.85K | 137,987 |
| Natarajan Sethuraman President, Research & Develop. | Mar 3, 2026 | Tax withholding | −7,577 | $11.76 | $89.11K | 242,224 |
| Dipal Doshi CEO, Director | Mar 3, 2026 | Tax withholding | −19,181 | $11.76 | $225.57K | 526,014 |
| Kory James Wentworth Chief Financial Officer | Mar 3, 2026 | Tax withholding | −5,712 | $11.76 | $67.17K | 145,975 |
| Nathan J. Dowden President & COO | Mar 3, 2026 | Tax withholding | −14,038 | $11.76 | $165.09K | 213,598 |
| Natarajan Sethuraman President, Research & Develop. | Mar 2, 2026 | Tax withholding | −3,898 | $11.66 | $45.45K | 249,801 |
| Dipal Doshi CEO, Director | Mar 2, 2026 | Tax withholding | −9,869 | $11.66 | $115.07K | 545,195 |
| Kory James Wentworth Chief Financial Officer | Mar 2, 2026 | Tax withholding | −2,939 | $11.66 | $34.27K | 151,687 |
| Nathan J. Dowden President & COO | Mar 2, 2026 | Tax withholding | −7,223 | $11.66 | $84.22K | 227,636 |
| Natarajan Sethuraman President, Research & Develop. | Mar 1, 2026 | Award | +55,800 | – | – | 253,699 |
| Dipal Doshi CEO, Director | Mar 1, 2026 | Award | +139,400 | – | – | 555,064 |
| Kory James Wentworth Chief Financial Officer | Mar 1, 2026 | Award | +44,600 | – | – | 154,626 |
| Nathan J. Dowden President & COO | Mar 1, 2026 | Award | +55,800 | – | – | 234,859 |
| Kory James Wentworth Chief Financial Officer | Nov 21, 2025 | Sale(10b5-1 plan) | −8,910 | $9.98 | $88.92K | 110,026 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
8.46%
3M shares short
Days to cover
6.9
At 0M shares a day
Change since last report
-14.2%
From 3M shares
Short volume, 20 days
42.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Entrada Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 47,862 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P. Affiliated stockholder | Aug 10, 2026 | 331,156 | $2.17M | Jul 30, 2026 | Venture Financing Investment |
| 5AM Ventures V, L.P. Affiliated stockholder | Jul 30, 2026 | 331,156 | $2.17M | Jul 30, 2026 | Venture Financing Investment |
| Nathan J. Dowden Officer | May 4, 2026 | 15,000 | $217.50K | May 4, 2026 | Exercise of Stock Options |
| Natarajan Sethuraman Officer | May 4, 2026 | 25,907 | $375.65K | May 4, 2026 | Restricted Stock Units |
| Kory James Wentworth Officer | Apr 1, 2026 | 2,500 | $31.55K | Apr 1, 2026 | Previously Exercised Stock Options |
| Kory James Wentworth Officer | Mar 9, 2026 | 16,477 | $207.28K | Mar 9, 2026 | Previously Exercised Stock Options |
| Nathan J. Dowden Officer | Mar 9, 2026 | 15,010 | $188.83K | Mar 9, 2026 | Restricted Stock Units |
| Kory James Wentworth Officer | Mar 4, 2026 | 7,988 | $94.66K | Mar 4, 2026 | Restricted Stock Units |
| Kory James Wentworth Officer | Nov 21, 2025 | 8,910 | $81.70K | Nov 21, 2025 | Restricted Stock Units |
| 5AM Ventures V, L.P. Affiliated Stockholder | Nov 14, 2025 | 200,000 | $1.76M | Nov 14, 2025 | Venture Financing Investment |
| 5AM Ventures V, L.P. Director | Jul 9, 2025 | 20,065 | $150.53K | Jul 9, 2025 | Venture Investment |
| 5AM Opportunities I, L.P. Director | Jul 9, 2025 | 6,935 | $52.03K | Jul 9, 2025 | Venture Investment |
| 5AM Ventures V, L.P. Director | Jul 1, 2025 | 18,578 | $132.32K | Jul 1, 2025 | Venture Investment |
| 5AM Opportunities I, L.P. Director | Jul 1, 2025 | 6,422 | $45.74K | Jul 1, 2025 | Venture Investment |
| 5AM Opportunities I, L.P. Director | Jun 30, 2025 | 6,422 | $43.75K | Jun 30, 2025 | Venture Investment |
See a number that looks wrong?